Home > Selected Past Studies

SELECTED PAST STUDIES - All Cancers - Hematological Cancers

Study

Disease

type & number of samples

Specific Requirements

associated data required

HEM-1

Acute Myeloid Leukemia

Bone Marrow Mononuclear Cells

Retrospective

More than 20 subjects

  • Relapsed or refractory AML patients
  • 5-10 million BMMCs per subject
  • Viably frozen
  • Age, Gender, Ethnicity
  • Medical history
  • Diagnosis report

HEM-2

Acute Myeloid Leukemia

Whole Blood & PBMC

Prospective

More than 10 subjects

  • Relapsed or refractory AML patients
  • Samples collected before any treatment
  • 20 ml whole blood collected on 3 different types of collecting tubes.
  • PBMCs isolated right after blood collection and frozen at -80°C
  • Blood Samples per patient must be shipped immediately after collection
  • Age, Gender, Ethnicity
  • Treatment history
  • Diagnosis

HEM-3

Chronic Myeloid Leukemia

RNA

Retropective

More than 180 subjects treated by TKI

2 groups:

  • 50% cases with an event (death, loss of Response, appearance of mutation…)
  • 50% cases without an event (event-free at least 6 months after blood draw
  • Subjects treated by Tyrosine Kinase Inhibitors treatment
  • Demographic, diagnostic and medical data
  • Confirmed diagnosis of BCR-ABL positive Chronic Myeloid Leukemia
  • Treatment History and medical out-come

HEM-4

Diffuse Large B-Cell Lymphoma (DLBCL)

FFPE Blocks

Retrospective

More than 15 subjects

  • Lymph node biopsy tissue blocks
  • Subjects with newly diagnosed DLBCL
  • Demographic, diagnostic and medical data
  • Treatment History

HEM-5

Diffuse Large B Cell Lymphoma (DLBCL)

FFPE Blocks

Retrospective

More than 50 subjects

  • Lymph node biopsy tissue blocks
  • Relapsed and refractory DLBCL
  • Last line of therapy must have been chemotherapy based regimen
  • Age, Gender, Ethnicity
  • Date of collection
  • Clinical history
  • Age, Gender, Ethnicity
  • Date of collection
  • Clinical history
  • Pathology report
  • Information about response to last line of therapy (response and progression free survival)

HEM-6

Peripheral T-Cell Lymphoma

FFPE Blocks

Retrospective

At least 20 subjects

  • Lymph node biopsy tissue blocks from T-cell lymphomas:
  • Cutaneous
  • Angioimmunoblastic
  • Extranodal natural killer/ T-cell lymphoma
  • Nasal type
  • Enteropathy type
  • Subcutaneous panniculitis-like
  • Anaplastic large cell lymphoma
  • Age, Gender, Ethnicity
  • Clinical history
  • Pathology report

HEM-7

Mantle Cell Lymphoma

Peripheral Blood Mononuclear Cells and Isolated B-cells/Blasts

Retrospective

More than 10 subjects

  • Newly diagnosed untreated patients
  • Age, Gender, Ethnicity
  • Sample collection date (year only)
  • Clinical history
  • Diagnosis report

HEM-8

T-Cell Lymphoma

FFPE Blocks

Retrospective

More than 60 subjects

6 groups:

  • Adult T-Cell Leukemia/Lymphoma HTLV1+
  • NK/T Lymphoma, nasal type
  • Enteropathy-associated T Lymphoma
  • Peripheral T-Cell Lymphoma
  • T-Cell Lymphoma, NOS
  • Angioimmunoblastic T-Cell Lymphoma
  • Lymph nodes or biopsy tissue blocks
  • Age, Gender, Ethnicity
  • Medical history
  • Diagnosis report

HEM-9

Lymphoma (Pediatric)

FFPE Blocks

Prospective

More than 25 subjects

  • Lymph node biopsy or surgical resection tissue blocks
  • Age, Gender, Ethnicity
  • Sample collection date
  • Confirmed Pathological diagnosis
  • Date of initial diagnosis

HEM-10

ALK-positive Anaplastic Lymphoma

FFPE Blocks

Retrospective

More than 5 subjects

  • ALK mutated
  • Age, Gender, Ethnicity
  • Pathological diagnosis
  • Sample collection date
  • Used method for detection of ALK rearrangements

HEM-11

Multiple Myeloma

Frozen Bone Marrow Biopsy

Prospective

More than 20 subjects

2 groups:

  • Subjects with Relapsed or Refractory MM
  • Newly diagnosed MM subjects, treatment naïve
  • Patients under treatment at the time of collection
  • Age, Gender, Ethnicity
  • Sample collection date
  • Confirmation of Diagnosis
  • Treatment history

HEM-12

Multiple Myeloma

Frozen EDTA plasma-Red Blood Cell-lysed Bone Marrow Aspirate Cell Pellet-Bone Marrow FFPE Clot

Retrospective

More than 5 subjects 

  • Minimum of 0.5 mL of BMA to be used for cell pellet and FFPE clot samples
  • Age, Gender, Ethnicity
  • Clinical history
  • Pathology report